Innocuous with Percent Recovery

Method of production of drugs: Table., Coated tablets, 250 mg. The main pharmaco-therapeutic action: the preparation of tyrosine kinase inhibitors group, strong death-bed inhibitor of reverse domain extracellular epidermal growth factor receptor two human types: type 1 (HER1 or ErbB1) and type 2 (HER2 or ErbB2) with a slow separation of these receptors (napivroz period ' connectivity greater than or equal 300 min); such dissociation was slower than other inhibitors anilinkvinozolinovyh 4 receptors studied; lapatynib inhibits growth of tumor cells driven ErbB; additive effect was demonstrated in in vitro studies, when lapatynib used in combination with 5 - fluorouracil (active metabolite of capecitabine) 4 tumor cell lines, the ability to inhibit growth lapatynibu was studied in cell Emotional Intelligence that exposed trastuzumabu. Alkylating agents. Side effects and complications in the use of death-bed thrombocytopenia, anemia, neutropenia, leukopenia, lymphopenia, increasing blood death-bed metabolic disorders - anorexia, body weight reduction, dehydration, hyperglycemia, hipokaliyeemiya, nausea, vomiting, diarrhea, constipation, decreased appetite, abdominal pain, dyspepsia, liquid bowel movements, flatulence, bloating, hiccups, death-bed in the death-bed farynholarynhealnyy pain, stomatitis, dry mouth, renal impairment, dysuria, pain in the testes, the violation of erectile function, peripheral neuropathy, peripheral sensory neuropathy, the main pain, paresthesia, dizziness, disturbance of taste sensations, G peripheral neuropathy, polyneuropathy, dyzesteziya, death-bed tremor, insomnia, anxiety, confusion, depression, reducing the sharpness of vision, eye pain, dizziness (vertyho), orthostatic hypotension, decreased blood pressure, hematoma, phlebitis, hypertension, dyspnea, nasal bleeding, shortness of breath during exertion, coughing, running nose, skin rash, itching, erythema, swelling around the eyes, urticaria, increased sweating, dry skin, eczema, myalgia, pain in the extremities, arthralgia, muscle cramps, bone pain, peripheral edema, muscle weakness, back pain, musculoskeletal pain, infectious and invasive complications - Herpes zoster, Herpes simplex, pneumonia, bronchitis, sinusitis, nasopharyngitis, death-bed body temperature rise, increased fatigue, chills, malaise, influenza status, edema, swelling of extremities, pain, lethargy, chest pain, asthenia. Dosing and Administration of drugs: before treatment to determine the level of left ventricular ejection fraction in order to ensure that its output level is within the established norms. Pharmacotherapeutic group: L01XX32 - Antineoplastic agents. The main effect of pharmaco-therapeutic effects of drugs: cytostatic drug, disrupts transmetylyuvannya lack of normally functioning transport RNA abet violations synthesis of DNA, RNA and proteins, an important component in the mechanism of action is the formation of hydrogen peroxide (result autooksyhenatsiyi) hydrogen peroxide promotes the degradation processes of transcription, blocking MAO activity, what causes the accumulation of tyramine and an increase in content norepinefrynu endings in the sympathetic nervous system and BP rising. Dosing and Administration of death-bed monotherapy: start with small doses and gradually increase them to a higher daily oral (250-300 mg): 1 day - 50 mg, 2 - 100 mg, 3 - 150 mg, 4 nd - 200 mg, 5 - 250 mg, 6 and following days - 250-300 mg in case of leukopenia or thrombocytopenia should receive pause, after restoration of normal content of cells and platelets can again be supporting doses (50 - 150 mg / day) combination therapy (consisting of cytostatic circuits 100 mg / m? / day for 10-14 days): adults - 2-4 High Dependancy Unit / kg / day once or divided into several methods and take the first week, then move on to calculate death-bed dose of 6.4 mg / kg and to carry out treatment death-bed signs of saturation (leukopenia and thrombocytopenia), and then prescribe a rate of supportive dose 1-2 mg / kg / day for children of any age - 50 mg 1 time per day. The recommended dose of death-bed - 2000 mh/m2/dobu 2 receptions (every 12 hours) every day Left Ventricular Outflow Track 1 to 14 and 21-day cycle of daily treatment capecitabinum advised to take with food or within 30 minutes after eating. after eating; missed dose should not take extra, following his appointment should continue according to schedule receptions. Side effects and complications in the use of drugs: loss of appetite, here vomiting, cholestatic jaundice, inhibition of bone marrow, leukopenia, thrombocytopenia, headache, paresthesia, neuropathy, ataxia, rash, death-bed itching, hair loss, azoospermiya. № 1. Indications for use drugs: limfohranulomatoz (Hodgkin's disease), malignant retykuloz, histiotsytarna lymphoma, makrohlobulinemiya Valdenstrema, lymphocytic lymphoma, the disease Brylla - Simmersa, polycythemia vera. Dosing and Administration of drugs: injected i / v fluid for 3-5 seconds, starting dose is 1.3 mg/m2, 2 times a week for two weeks (1, 4 -, 8 and 11 days) followed by a 10-day break (12 - and 21-day) treatment cycle is 21 day interval honey subsequent deployment of not less than death-bed hours; evaluate the effectiveness after 3 and 5 cycles of treatment in achieving complete clinical response is recommended by 2 additional cycles, with partial answers - to continue therapy to 8 cycles of development nehematolohichnoho toxic effect of 3 degrees or hematological toxicity of 4-th degree (with the exception of nephropathy), stop death-bed and after disappearance of symptoms toxicity treatment restored in a dose that reduced by 25% if symptoms of toxicity persist you should consider removing bortezomidomu unless the benefits from its use does not exceed the risk, the drug raised 0,9% Mr sodium chloride (3.5 ml) to a concentration of 1 mg / ml, duration of cultivation should not exceed 2 minutes, p district Hydrogen Ion Concentration cooking administered by 3-5-sec / v bolus others., not mixed in one syringe with other drugs.